Madam Chair, I can give a brief answer on the issue of capacity.
The countries that the honourable member mentioned generally had in place at the outset of the pandemic substantially greater biomanufacturing assets available. South Korea has huge biomanufacturing capability, as Minister Champagne mentioned. The Serum Institute of India, that one facility alone, is slated to be producing more than a billion shots for COVID.
These large multinationals, when they were looking to produce and looking to dedicate scarce resources to technology transfer, were looking for facilities that could produce at scale. As has already been noted, Canada did not have surplus capacity to produce at scale. Certainly, the facilities we do have—and there are excellent companies here—either had the wrong technology or were already dedicated to vital products, such as for pertussis, polio, diphtheria and those sorts of things.
I'll stop there.